AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Sep - Alivus Life Sciences will attend Kotak Healthcare Forum 2026 on September 17, 2026 in Mumbai.
Source: Bse
Alivus Life Sciences Limited (ALIVUS)
Large CapPharma stocks · Large cap · NSE
Alivus Life Sciences Limited, formerly Glenmark Life Sciences, is an Indian API manufacturer. It focuses on generic APIs and CDMO services, serving regulated and emerging markets globally. The company emphasizes R&D in complex molecules, high-potency APIs, and iron complexes.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals14 Oct 2026 · screener
Latest result31 Jul, 12:20 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage10/14 · 71%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
66BullishSMA20 -2.0% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 44
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
ALIVUSD candles · FIT view+20.8%Latest close ₹1268.60 on 2026-10-19
Bar
-3.1%
RSI
33
MACD hist
-9.78
52W pos
67%
2026-10-19O ₹1309.50H ₹1324.90L ₹1256.20C ₹1268.60Vol 1.4L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ALIVUSNifty PharmaNifty 500
- ALIVUS
- +12.0%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +17.6 pp
Chart stats
19 Oct 2026- From 52W high
- -15.1%
- 52W range position
- 67%
- ATR (14)
- 3.6%
- Volume vs 20D
- 1.18x
- Avg traded value
- ₹14.5 Cr
- 20D price channel
- ₹1,256.2 - ₹1,446
₹1,493.8
₹819 - ₹1,493.8
₹45.2
Latest completed session
20-session average
21.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED29
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good60
Revenue +6.3% · PAT +31.1% YoY
Technical
Bullish66
Price trend and sector-relative-strength timing.
Valuation
Legacy model+13.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence72
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 60/100Rev +6% YoY · PAT +31% YoY · margin expansion · operating leverage
Filed 30 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹640 Cr | +6.3% | -7.1% |
| EBITDA | ₹212 Cr | +23.3% | -1.4% |
| Operating margin | 33.0% | +400 bps | +200 bps |
| PAT | ₹160 Cr | +31.1% | -1.8% |
| PAT margin | 25.0% | +473 bps | +134 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 47.00
- P/B
- —
- EV/EBITDA
- 26.46
- Market Cap
- 16514.00Cr
Profitability
- ROE
- —
- ROCE
- —
- ROA
- —
- Dividend Y
- 0.37%
Growth (CAGR)
- Revenue 5Y
- 15.00%
- EPS 5Y
- 15.00%
- Revenue 3Y
- 27.00%
- EPS 3Y
- 27.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 6.72×
- Altman Z
- 0.00
- Book Value
- —
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 0/5
- OCF
- —
- EPS TTM
- 32.61
Shareholding
- Promoter Hold
- 74.87%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 78%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 2,552+6.9% vs prev
Net Profit
₹ CrLatest: 564+16.0% vs prev
Return on Equity
%Latest: 2,256+15373.3% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 33.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~2.1% over last month) — short-term momentum negative.
- RSI(14) at 33 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 15% off 52W high · 55% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
84
RS percentile
Stage 2 UptrendEstablished S2
1M return
-11.3%
3M return
+12.0%
6M return
+20.0%
1Y return
+40.0%
RS 1D
0
RS 20D
-2
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 7.8% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +5.2%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
13 Apr 2026
S2 age
134 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 139.19-2.12%
RS vs Nifty 500139
Valuation & peers
U-Score 29 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 29 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation4/30
Growth14/25
Quality0/20
Balance Sheet8/15
Cash Flow0/10
Piotroski
5/9 (+3)
Penalties
0
Raw sum
29
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
29/100 · legacy band OVERVALUED
Positive drivers
- Fair-value margin of safety is positive at 13.6%.
- Growth contributes 14/25 to the score.
- Balance sheet contributes 8/15 to the score.
Main drags
- Altman Z is 0.0, in distress territory.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
47.0
PB
—
EV/EBITDA
26.5
ROE
—
ROCE
—
FCF Yield
—
Debt/Equity
0.0
MoS
+13.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
29
Previous: 29
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
+13.6%
Previous: +13.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
47
47
47
47
47
27
27
27
29
29
29
29
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
45.0
Growth-justified Value
₹1,467.45
+13.6% MoS
PEG
2.37
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
PFIZER
Large
Pfizer Limited
Pharmaceuticals
match 167
33
117.0
19.8%
-738%
WATCHLIST
ERIS
Large
Eris Lifesciences Limited
Pharmaceuticals
match 166
55
24.5
18.7%
+47%
FAIR VALUE
CAPLIPOINT
Large
Caplin Point Laboratories Limited
Pharmaceuticals
match 165
61
26.3
20.9%
+43%
UNDERVALUED
APLLTD
Mid
Alembic Pharmaceuticals Limited
Pharmaceuticals
match 161
34
21.0
13.4%
-455%
WATCHLIST
ASTRAZEN
Small
AstraZeneca Pharma India Limited
Pharmaceuticals
match 160
43
85.2
23.3%
-98%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis intactReviewed 2026-10-11T13:44:09.172Z
Management commentary snapshot
Q1 FY27 revenue grew 6.4% YoY to ₹6,404 Mn, driven by 26.5% YoY growth in non-GPL business. EBITDA rose 29.1% YoY to ₹2,341 Mn, with margins expanding 650 bps YoY to 36.6%. PAT increased 31.8% YoY to ₹1,601 Mn.
Alivus delivered strong Q1 FY27 results, primarily driven by robust growth in its non-GPL business and significant margin expansion. While the GPL segment faced a sharp decline due to inventory rationalization, management expects a recovery in H2 FY27 and maintains its full-year revenue and EBITDA margin guidance, suggesting the core thesis remains on track.
Current business mix
Revenue by Segment (Q1 FY27)
Latest issuer-disclosed distribution across 2 reported categories.
GPL11.3%
Non-GPL88.7%
Growth engines
Non-GPL Business Momentum
Non-GPL business continued its strong growth trajectory, reporting 27.6% QoQ and 26.5% YoY growth, driven by healthy demand and new product launches.
CDMO Ramp-up
CDMO business saw 3.8% YoY growth in Q1 FY27, with contributions from new and existing projects expected to translate into better growth in H2 FY27.
Complex API Platforms
HP API portfolio has 29 products in active development, with 13 validated. Iron complexes portfolio is advancing, with one regulatory filing completed.
New Product Launches
Recently launched products are continuing to gain scale across geographies, contributing to strong non-GPL performance.
Capacity and execution
Ankleshwar Brownfield Expansion
Planned addition of ~100KL capacity at Ankleshwar facility, expected to be operational by Q4 FY27.
Dahej Brownfield Expansion
Planned addition of ~160KL capacity at Dahej facility, expected to be operational by Q3 FY27.
Solapur Greenfield Expansion (Phase 1 & 2)
Construction work for 465 KL capacity (Phase 1 & 2) at Solapur is in process, expected to be operational by Q3 FY27 and Q4 FY27 respectively.
New R&D Facility
Construction has begun for a new R&D facility in Taloja (Navi Mumbai) focusing on flow chemistry, complex products, and oncology research.
Tailwinds
Healthy Demand
Strong momentum across all geographies reflects healthy demand, particularly in the non-GPL business and regulated markets.
Favorable Product Mix
Gross Margins improved due to a favorable product mix and contributions from new launches.
Headwinds
GPL Business De-growth
GPL business witnessed a de-growth of 52.6% YoY in Q1 FY27 on account of inventory rationalization.
Risk radar
GPL Business Recovery
The GPL business experienced a significant decline in Q1 FY27, with recovery expected in H2 FY27 to achieve a flattish full-year performance.
Geopolitical Uncertainties
Product mix remained largely stable despite ongoing geopolitical uncertainties, indicating a potential background risk.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
YoY comparison is essential for assessing underlying business growth and margin expansion, especially given the seasonal nature of the GPL business. QoQ is relevant for tracking sequential momentum in the non-GPL segment and operational efficiencies.
Sector KPIs management disclosed
Non-GPL Business Growth
Non-GPL business grew 27.6% QoQ and 26.5% YoY, driven by strong momentum across all geographies and increasing contributions from new product launches.
Regulated Markets Contribution
Regulated markets contributed 83% of Q1 FY27 revenues, supported by healthy demand across geographies.
Cumulative DMF/CEP Filings
Cumulative DMF/CEP filings reached 617 as of June 30, 2026, across major markets including US, Europe, Japan, and Brazil.
R&D Spend
R&D spend was ₹237 Mn in Q1 FY27, representing 3.7% of total revenue.
Management forward view
FY27 Revenue Growth Outlook
Management remains confident of achieving revenue growth of 10% - 12% in FY27, driven by strong non-GPL momentum.
FY27 EBITDA Margin Outlook
Management expects to sustain EBITDA margins in the 30%–32% range for FY27.
GPL Business Expectation
GPL business is expected to be flattish in FY27, despite a significant Q1 decline, with historical skew towards H2.
Investments for Future Growth
Ongoing investments in capacity expansion and pipeline development are strengthening the foundation for future growth.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Non-GPL Business Growth | 26.5% YoY in Q1 FY27 | Continued strong momentum and increasing contributions from new product launches. |
| GPL Business Recovery | Down 52.6% YoY in Q1 FY27 | Evidence of recovery in H2 FY27 to achieve management's flattish full-year expectation. |
| EBITDA Margin Sustainability | 36.6% in Q1 FY27 | Maintenance of margins within the 30%-32% guided range for FY27, despite potential product mix shifts. |
| Capacity Expansion Progress | Ankleshwar, Dahej, Solapur expansions underway | Timely commissioning and ramp-up of new capacities as per planned operational timelines (Q3/Q4 FY27). |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
72Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 69th percentile of the scored universe and 58th percentile within Pharma. Main check: cash conversion is weak at 43/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
83 docs text-extracted · 30 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
69th percentile
overall median 67 · Pharma: 58th pctile, median 70 · Large: 46th pctile, median 73
Evidence depth
Financial-only
83 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
87
strong · quarterly consistency
Trust positives
- ▸Promoter holding is 74.9%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.00.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Only 0 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Alivus Life Sciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 Sep - Investor/analyst meetings with various MF/institutions scheduled in Mumbai on September 10-11, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Sep
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 18 Aug - Alivus Life Sciences to acquire 76% stake in IQGenX for INR 91.2 million, closing expected by year-end.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Acquisition 18 Aug - Board approved 76% stake acquisition in IQGEN-X Pharma for about Rs 9.12 crore.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Aug - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug - Newspaper Advertisement of Notice of 15th Annual General Meeting and E-Voting information.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Jun - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Analyst / Institutional Investor Meeting.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Jun - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 20 May - Alivus Life Sciences to meet investors on May 25 and 27, 2026 in Mumbai.
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.